Results of the present study align with those of Verboom et al. [41], who similarly found no significant effect of the CYP2C8*3 on imatinib pharmacokinetics in Dutch patients with GIST or CML. The gene discussed is CYP2C8; the disease is gastrointestinal stromal tumor.